- Home
- VATE vs NTRB Comparison
VATE vs NTRB Comparison
Compare VATE & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VATE | NTRB |
|---|---|---|
| Founded | 1994 | 2016 |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | Metal Fabrications | Industrial Specialties |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.2M | 42.4M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | VATE | NTRB |
|---|---|---|
| Price | $15.28 | $3.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 55.7K | 9.1K |
| Earning Date | 05-14-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,246,000,000.00 | N/A |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.55 | N/A |
| 52 Week Low | $3.75 | $3.21 |
| 52 Week High | $16.71 | $11.68 |
Technical Indicators
Market Signals| Indicator | VATE | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 66.82 | 43.51 |
| Support Level | $4.48 | $3.44 |
| Resistance Level | N/A | $4.24 |
| Average True Range (ATR) | 1.23 | 0.16 |
| MACD | 0.19 | 0.00 |
| Stochastic Oscillator | 77.92 | 56.65 |
Price Performance
Historical ComparisonAbout VATE INNOVATE Corp.
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments. Its segments include Infrastructure, Life Sciences and Spectrum, and Other segment. Through its subsidiaries it provides fully integrated structural and steel construction services; supports healthcare and biotechnology product development; and operates Over-The-Air (OTA) broadcasting stations across the United States (U.S.) including Puerto Rico.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.